Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

The growing role of NIR-II imaging in preclinical research

NIR-II imaging has many advantages for preclinincal research as it supports deeper visualization with lower scattering and autofluorescence.

From Scintica Instrumentation Inc. 29 May 2026

Drug-filled nanofibers offer potential breakthrough treatment for brain cancer

Researchers with the University of Cincinnati and Johns Hopkins Medicine developed a potential treatment for brain cancer that uses nanofibers embedded with a combination of drugs that work in concert to target tumors.

28 May 2026

Scientists rethink GLP-1 delivery to improve dosing, tolerability, and adherence

The review highlights nanocarriers, microspheres, hydrogels, microneedles, long-acting formulations, and co-formulations as promising but mostly early-stage strategies that still require stronger long-term clinical evidence.

27 May 2026

Click chemistry advances precision oncology by merging imaging and therapyly

Conventional cancer treatments like chemotherapy often struggle with poor targeting, leading to severe systemic toxicity and drug resistance.

19 May 2026

Miniaturization in Medtech

Medical devices are becoming smaller, lighter and more portable. From handheld diagnostic tools to wearable infusion pumps and compact surgical instruments, reduced size is now a defining feature of many new Medtech products.

From SMB Bearings 19 May 2026

Low-frequency ultrasound waves directly manipulate blood flow properties

For decades, ultrasound has been associated with diagnostics – a routine scan in a hospital room, a monitor displaying organs, tissues, or the first image of a baby.

18 May 2026

Rocket Science Health validates targeted olfactory-cleft deposition in non-human primates ahead of the 4th Nasal Formulation & Delivery Summit

As the pace of modern drug discovery accelerates, the industry is increasingly recognizing that a breakthrough molecule is only as effective as its ability to reach the target site.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 15 May 2026

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

ExiVex Biopharma (formerly EmerRx Biopharma), a clinical-stage pharmaceutical company developing a proprietary dual-chamber intranasal drug delivery platform, today announced in-human pharmacokinetic (PK) data for its lead candidate EMRX-101, an intranasal naloxone product targeting opioid-induced respiratory depression.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 15 May 2026

New drug carrier improves cancer treatment by anchoring to tumors

Medications are designed to treat diseased tissues while sparing healthy ones, often by attaching the drug to something that helps guide it directly to its target. But drugs also need time to work, which means they need to stay near the diseased tissues long enough.

13 May 2026

Researchers find new way to deliver drugs directly into cancer cells

National University of Singapore Researchers at the National University of Singapore (NUS) have developed a high-throughput method to identify gold nanoparticles capable of delivering therapies directly to mitochondria (the energy centres inside cancer cells).

13 May 2026

Hovione and IDC Intranasal Drug Delivery Platform available for commercial partnerships

Hovione, a global integrated specialist CDMO, and Industrial Design Consultancy Ltd (IDC), an international product development company, today announced that their Intranasal Drug Delivery Platform has reached a new milestone, with its lead single-use nasal dry powder device now available for commercial partnerships.

From Hovione 11 May 2026

New nanoparticles disable drug resistance to achieve complete tumor elimination

Cancer cells frequently develop the ability to expel anticancer drugs before they can work -- a phenomenon called multidrug resistance (MDR) -- which is one of the leading reasons why chemotherapy fails in patients.

8 May 2026

Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage

Calla Lily Clinical Care, a women’s health-focused medical technology company, today announced dosing of the first patients in the FREEDOM clinical trial.

6 May 2026

Bacterial vesicles emerge as powerful tools against antibiotic resistance

Antibiotic resistance is making bacterial infections harder to treat, demanding new therapeutic strategies. A new review highlights bacterial extracellular vesicles (BEVs) as promising nanoscale tools that can kill pathogens, block infection, enhance vaccines, and deliver drugs.

25 Apr 2026

Hyperbaric oxygen therapy shows dual effects in glioblastoma treatment

Glioblastoma remains a highly challenging malignancy with a pronounced tendency for recurrence. The hypoxic microenvironment is a key contributor to its therapy resistance.

23 Apr 2026

Bioengineered chewing gum reduces cancer-linked oral microbes

Researchers led by Henry Daniell of the School of Dental Medicine have shown that extracts from bioengineered chewing gum reduce the levels of three microbes known to be associated with head and neck squamous cell cancer (HNSCC), paving the way for more effective and affordable therapies.

23 Apr 2026

Nature-inspired vesicles offer new path for precision medicine therapies

A quiet revolution is underway in modern medicine: Drug development is aiming to move from managing disease to correcting it through RNA and gene-editing therapies.

17 Apr 2026

Waters debuts industry-first extended-range MALS detector for UHPLC/UPLC, powering rapid characterization of large molecules

Waters Corporation today announced the launch of the Waters omniDAWN™ Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio.

From Waters Corporation 16 Apr 2026

Nanomedicine offers targeted solutions for breast cancer treatment

Breast cancer (BCA) is one of the most common cancers worldwide, with high mortality and morbidity in women.

10 Apr 2026

High affinity for immune receptors predicts antibody drug associated anaphylaxis risk

Antibody therapeutics are laboratory-made proteins designed to work like the body's natural antibodies. They are widely used to treat diseases such as cancer by binding to specific targets, including cancer cells or inflammatory molecules.

8 Apr 2026